CY1120147T1 - Biodegradable Ocular Implant - Google Patents

Biodegradable Ocular Implant

Info

Publication number
CY1120147T1
CY1120147T1 CY20181100250T CY181100250T CY1120147T1 CY 1120147 T1 CY1120147 T1 CY 1120147T1 CY 20181100250 T CY20181100250 T CY 20181100250T CY 181100250 T CY181100250 T CY 181100250T CY 1120147 T1 CY1120147 T1 CY 1120147T1
Authority
CY
Cyprus
Prior art keywords
ocular implant
biodegradable ocular
implants
ophthalmic region
plga
Prior art date
Application number
CY20181100250T
Other languages
Greek (el)
Inventor
David Weber
David Chou
Lin Peng
Thierry Nivaggioli
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of CY1120147T1 publication Critical patent/CY1120147T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)

Abstract

Η εφεύρεση παρέχει βιοαποικοδομήσιμα εμφυτεύματα καταλλήλου μεγέθους για εμφύτευση εντός μίας οφθαλμικής περιοχής και μεθόδους για την αγωγή ιατρικών καταστάσεων του οφθαλμού. Τα εμφυτεύματα σχηματίζονται από ένα μίγμα PLGA με υδρόφιλο άκρο και υδρόφοβο άκρο και χορηγούν δραστικούς παράγοντες εντός μίας οφθαλμικής περιοχής χωρίς υψηλή έκρηξη αποδέσμευσης.The invention provides biodegradable implants of appropriate size for implantation within an ophthalmic region and methods for treating medical conditions of the eye. The implants are formed from a mixture of PLGA with a hydrophilic end and a hydrophobic end and deliver active agents within an ophthalmic region without a high release burst.

CY20181100250T 2003-01-09 2018-02-28 Biodegradable Ocular Implant CY1120147T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/340,237 US20040137059A1 (en) 2003-01-09 2003-01-09 Biodegradable ocular implant
EP04700611A EP1581193B1 (en) 2003-01-09 2004-01-07 Biodegradable ocular implant
EP08002892.1A EP1917957B1 (en) 2003-01-09 2004-01-07 Biodegradable ocular implant

Publications (1)

Publication Number Publication Date
CY1120147T1 true CY1120147T1 (en) 2018-12-12

Family

ID=32711277

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20171100057T CY1118431T1 (en) 2003-01-09 2017-01-17 Biodegradable Ocular Implant
CY20181100250T CY1120147T1 (en) 2003-01-09 2018-02-28 Biodegradable Ocular Implant
CY20191100615T CY1121731T1 (en) 2003-01-09 2019-06-13 BIODEGRADABLE EYE IMPLANT
CY20191100865T CY1121912T1 (en) 2003-01-09 2019-08-13 BIODEGRADABLE EYE IMPLANT

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20171100057T CY1118431T1 (en) 2003-01-09 2017-01-17 Biodegradable Ocular Implant

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20191100615T CY1121731T1 (en) 2003-01-09 2019-06-13 BIODEGRADABLE EYE IMPLANT
CY20191100865T CY1121912T1 (en) 2003-01-09 2019-08-13 BIODEGRADABLE EYE IMPLANT

Country Status (21)

Country Link
US (1) US20040137059A1 (en)
EP (6) EP3563839A1 (en)
JP (1) JP4223040B2 (en)
KR (1) KR20050099008A (en)
CN (2) CN101259280A (en)
AT (1) ATE555779T1 (en)
AU (1) AU2004204744B2 (en)
BR (2) BRPI0406692A (en)
CA (1) CA2512315C (en)
CY (4) CY1118431T1 (en)
DK (5) DK3305284T3 (en)
ES (5) ES2613028T3 (en)
FR (1) FR12C0067I1 (en)
HK (1) HK1084021A1 (en)
HU (4) HUE044965T2 (en)
MX (1) MXPA05007342A (en)
NZ (1) NZ540451A (en)
PT (4) PT1917957T (en)
SI (3) SI2799064T1 (en)
TR (2) TR201908857T4 (en)
WO (1) WO2004062649A2 (en)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20060280774A1 (en) * 1995-06-02 2006-12-14 Allergan, Inc. Compositions and methods for treating glaucoma
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
JP2004514702A (en) 2000-11-29 2004-05-20 オキュレックス　ファーマシューティカルズ，　インコーポレイテッド Intraocular implant for preventing transplant rejection in the eye
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20130041025A1 (en) 2002-02-04 2013-02-14 Allergan, Inc. Compositions and methods for treating hair loss, hair thinning, and hair color loss
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US8246974B2 (en) 2003-05-02 2012-08-21 Surmodics, Inc. Medical devices and methods for producing the same
EP1633320A2 (en) 2003-05-02 2006-03-15 SurModics, Inc. Implantable controlled release bioactive agent delivery device
US7060723B2 (en) 2003-08-29 2006-06-13 Allergan, Inc. Treating neurological disorders using selective antagonists of persistent sodium current
US7125908B2 (en) * 2003-08-29 2006-10-24 Allergan, Inc. Treating pain using selective antagonists of persistent sodium current
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
DE602005011928D1 (en) 2004-01-20 2009-02-05 Allergan Inc COMPOSITIONS FOR LOCALIZED THERAPY OF THE EYE, PREFERABLY CONTAINING TRIAMCINOLONE ACETONIDE AND HYALURONIC ACID
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20050244461A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
KR20070095921A (en) * 2004-12-10 2007-10-01 탈리마 테라퓨틱스 인코포레이티드 Compositions and methods for treating conditions of the nail unit
US20060204548A1 (en) * 2005-03-01 2006-09-14 Allergan, Inc. Microimplants for ocular administration
AU2011236024B2 (en) * 2005-03-01 2013-05-23 Allergan, Inc. Microimplants for ocular administration
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
EP1917971A1 (en) * 2006-10-27 2008-05-07 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Substained release formulations comprising very low molecular weight polymers
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8536190B2 (en) * 2007-01-30 2013-09-17 Allergan, Inc. Treating unwanted ocular conditions using an ascomycin macrolactam
EP2134350A1 (en) * 2007-03-14 2009-12-23 The University of Washington Device and method for intraocular drug delivery
US20080317805A1 (en) * 2007-06-19 2008-12-25 Mckay William F Locally administrated low doses of corticosteroids
CN101984745B (en) * 2007-09-07 2013-08-14 Qlt股份有限公司 Drug cores for sustained release of therapeutic agents
US8353862B2 (en) 2007-11-02 2013-01-15 Allergan, Inc. Drug delivery systems and methods
US8524267B2 (en) * 2008-04-18 2013-09-03 Warsaw Orthopedic, Inc. Dexamethasone formulations in a biodegradable material
US9125917B2 (en) * 2008-04-18 2015-09-08 Warsaw Orthopedic, Inc. Fluocinolone formulations in a biodegradable polymer carrier
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10588855B2 (en) 2008-05-12 2020-03-17 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
CN102026599A (en) 2008-05-12 2011-04-20 犹他大学研究基金会 Intraocular drug delivery device and associated methods
US20110206773A1 (en) * 2008-05-20 2011-08-25 Yale University Sustained delivery of drugs from biodegradable polymeric microparticles
EP2296621A1 (en) * 2008-05-20 2011-03-23 Yale University Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use
CN101612111B (en) * 2008-06-24 2011-11-23 上海医药工业研究院 Sustained-release microsphere of nomegestrol acetate of analogs thereof and preparation method and application thereof
US20110125090A1 (en) * 2008-11-13 2011-05-26 Peyman Gholam A Ophthalmic drug delivery system and method
US10272035B2 (en) 2008-11-13 2019-04-30 Gholam A. Peyman Ophthalmic drug delivery method
US10842669B2 (en) 2008-11-13 2020-11-24 Gholam A. Peyman Ophthalmic drug delivery method
US20100204325A1 (en) * 2009-02-11 2010-08-12 Allergan, Inc. Valproic acid drug delivery systems and intraocular therapeutic uses thereof
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US20100303794A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases
US20100303783A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases
US20100303788A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases
US20100303757A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases
CN102574900A (en) 2009-08-14 2012-07-11 阿勒根公司 Methods of treating cancer using opioid retargeted endpeptidases
EP2464365A2 (en) 2009-08-14 2012-06-20 Allergan, Inc. Methods of treating cancer using tachykinin retargeted endopeptidases
AU2010282274A1 (en) 2009-08-14 2012-03-15 Allergan, Inc. Methods of treating cancer using growth factor retargeted endopeptidases
WO2011020056A2 (en) 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using galanin retargeted endpeptidases
KR20120062772A (en) 2009-08-14 2012-06-14 알러간, 인코포레이티드 Methods of treating cancer using glucagon-like hormone retargeted endopeptidases
AU2010282276A1 (en) 2009-08-14 2012-03-15 Allergan, Inc. Methods of treating cancer using neurotrophin retargeted endopeptidases
EP2534137B1 (en) 2010-02-08 2015-09-16 Allergan, Inc. Pyridazine derivatives useful as cannabinoid-2 agonists
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
US20120207704A1 (en) 2011-02-14 2012-08-16 Allergan, Inc. Inhibiting Aberrant Blood Vessel Formation Using Growth Factor Retargeted Endopeptidases
WO2012112420A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Treatments using psma ligand endopeptidases
US20120207733A1 (en) 2011-02-14 2012-08-16 Allergan, Inc. Treating a Disease of Hyperproliferation Using Retargeted Endopeptidases
US20120207743A1 (en) 2011-02-14 2012-08-16 Allergan, Inc. Inhibiting Aberrant Blood Vessel Formation Using Retargeted Endopeptidases
WO2012112432A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Methods of inhibiting aberrant blood vessel formation using opioid retargeted endopeptidases
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
MX351261B (en) 2012-06-01 2017-10-06 Surmodics Inc Apparatus and method for coating balloon catheters.
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
US20150290170A1 (en) 2012-10-26 2015-10-15 Allergan, Inc. Ketorolac-containing sustained release drug delivery systems
JP6486279B2 (en) * 2013-01-15 2019-03-20 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ Lacrimal drug delivery device
RU2015143995A (en) 2013-03-14 2017-04-20 Халлюкс, Инк. METHOD FOR TREATING INFECTIONS, DISEASES OR DISEASES OF THE NAIL LODGE
US9492316B2 (en) * 2013-10-31 2016-11-15 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
RU2728195C2 (en) * 2014-02-26 2020-07-28 Аллерган, Инк. Device for delivery of intraocular implant and methods of its use
WO2015184173A1 (en) 2014-05-29 2015-12-03 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
WO2016040605A1 (en) 2014-09-11 2016-03-17 Psivida Us, Inc. Injector apparatus
FR3028410A1 (en) 2014-11-18 2016-05-20 Pierre Coulon MULTIFUNCTIONAL CAPSULAR IMPLANT
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
USD851755S1 (en) 2015-10-22 2019-06-18 Eyepoint Pharmaceuticals Us, Inc. Ocular inserter
WO2017091404A1 (en) 2015-11-23 2017-06-01 The Regents Of The University Of Colorado, A Body Corporate Lacrimal system for drug delivery
CN109937025B (en) 2016-04-20 2022-07-29 多斯医学公司 Delivery device for bioabsorbable ocular drugs
CA3024912A1 (en) 2016-05-20 2017-11-23 The Regents Of The University Of Colorado, A Body Corporate Lacrimal drug delivery device
US11628466B2 (en) 2018-11-29 2023-04-18 Surmodics, Inc. Apparatus and methods for coating medical devices
US11819590B2 (en) 2019-05-13 2023-11-21 Surmodics, Inc. Apparatus and methods for coating medical devices

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4322323A (en) * 1980-12-01 1982-03-30 Alza Corporation Erodible device comprising surfactant for modifying the rate of erosion of the device
EP0052916B1 (en) * 1980-11-10 1985-01-02 Alza Corporation Erodible polymer containing erosion rate modifier
US4883457A (en) * 1983-08-18 1989-11-28 Drug Delivery Systems Inc. Disposable and/or replenishable transdermal drug applicators and methods of manufacturing same
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US6217911B1 (en) * 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
JPS63291419A (en) * 1987-05-24 1988-11-29 Tatsumo Kk Heat treatment device
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (en) * 1990-11-30 1999-05-01 요시다 쇼오지 A controlled-release pharmaceutical preparation for intra-ocular implant
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5707643A (en) * 1993-02-26 1998-01-13 Santen Pharmaceutical Co., Ltd. Biodegradable scleral plug
EP0654256B1 (en) 1993-02-26 2000-08-02 Santen Pharmaceutical Co., Ltd. Biodegradable sclera plug
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6369116B1 (en) 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
JPH11509862A (en) * 1996-01-24 1999-08-31 アメリカ合衆国 New "burst-free" sustained release poly (lactide / glycolide) microspheres
KR20010014384A (en) * 1997-07-02 2001-02-26 모리타 다카카즈 Polylactic acid scleral plugs
US6306426B1 (en) * 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
JP2004514702A (en) * 2000-11-29 2004-05-20 オキュレックス　ファーマシューティカルズ，　インコーポレイテッド Intraocular implant for preventing transplant rejection in the eye

Also Published As

Publication number Publication date
ES2735132T3 (en) 2019-12-16
JP2006525953A (en) 2006-11-16
DK3305284T3 (en) 2019-08-19
CN101259280A (en) 2008-09-10
CY1121912T1 (en) 2020-10-14
PT2799064T (en) 2018-03-06
DK2799064T3 (en) 2018-03-12
EP3305284B1 (en) 2019-05-15
WO2004062649A2 (en) 2004-07-29
CY1118431T1 (en) 2017-06-28
PT3187177T (en) 2019-06-27
HK1084021A1 (en) 2006-07-21
HUE036209T2 (en) 2018-06-28
ATE555779T1 (en) 2012-05-15
EP1917957A3 (en) 2011-06-15
DK1917957T3 (en) 2017-02-13
EP1917957A2 (en) 2008-05-07
WO2004062649A3 (en) 2004-11-04
PT3305284T (en) 2019-08-30
CN1735405A (en) 2006-02-15
CN100364514C (en) 2008-01-30
ES2742152T3 (en) 2020-02-13
PT1917957T (en) 2017-01-23
CA2512315A1 (en) 2004-07-29
AU2004204744A1 (en) 2004-07-29
CY1121731T1 (en) 2020-07-31
EP3563839A1 (en) 2019-11-06
FR12C0067I1 (en) 2012-12-14
TR201908857T4 (en) 2019-07-22
SI3305284T1 (en) 2019-11-29
HUE044965T2 (en) 2019-11-28
EP3187177B1 (en) 2019-03-20
DK3187177T3 (en) 2019-06-24
BR122015016901B8 (en) 2021-07-27
EP1581193A2 (en) 2005-10-05
MXPA05007342A (en) 2005-09-30
HUE030319T2 (en) 2017-05-29
CA2512315C (en) 2008-12-30
BRPI0406692A (en) 2005-12-20
KR20050099008A (en) 2005-10-12
EP2799064A1 (en) 2014-11-05
SI3187177T1 (en) 2019-09-30
ES2613028T3 (en) 2017-05-22
EP2799064B1 (en) 2017-11-29
ES2384875T3 (en) 2012-07-13
EP1581193B1 (en) 2012-05-02
NZ540451A (en) 2008-02-29
BR122015016901B1 (en) 2018-06-05
EP3305284A1 (en) 2018-04-11
US20040137059A1 (en) 2004-07-15
ES2661383T3 (en) 2018-03-28
DK1581193T3 (en) 2012-06-25
AU2004204744B2 (en) 2008-03-13
JP4223040B2 (en) 2009-02-12
SI2799064T1 (en) 2018-04-30
HUE044694T2 (en) 2019-11-28
TR201802793T4 (en) 2018-03-21
EP3187177A1 (en) 2017-07-05
EP1917957B1 (en) 2016-11-16

Similar Documents

Publication Publication Date Title
CY1120147T1 (en) Biodegradable Ocular Implant
CY1107823T1 (en) OPTICAL INFECTION WITH A DOUBLE EXTENDING PROCEDURE
JP2014128739A5 (en)
ATE404140T1 (en) DEVICE FOR INTRAOCULAR ADMINISTRATION OF ACTIVE INGREDIENTS
EP2772226A3 (en) Apparatus for creating ocular surgical and relaxing incisions
CY1115912T1 (en) Reduction of intraocular pressure with Pacemaker intraocular implants
HK1059037A1 (en) Methods and compositions for treatment of ocular neovascularization and neural injury
WO2006014484A3 (en) Methods and devices for the treatment of ocular conditions
AU3649502A (en) Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
WO2010019507A3 (en) Implantable drug delivery device and methods of treating male genitourinary and surrounding tissues
TW200505402A (en) Ophthalmic drug delivery device
MX2023000999A (en) Intraocular implant with high loading of a prostamide.
KR20200121564A (en) Medical member for insertion into in-vivo
AU2021903621A0 (en) An implant and surgical procedures for the implanting thereof
EP1547618A4 (en) Drug for auditory dysfunction
CZ2005565A3 (en) Cartridge for storing and/or introduction of eye implant